Tilly's (TLYS) IPO Opens Sharply Higher
Get Alerts TLYS Hot Sheet
Price: $5.91 -2.8%
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 6.4%
Revenue Growth %: +0.3%
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 6.4%
Revenue Growth %: +0.3%
Join SI Premium – FREE
The IPO for Tilly's, Inc. (NYSE: TLYS) opened for trading. Shares opened at $18.80 after pricing 8,000,000 shares at $15.50 per share, above the expected $11.50-$13.50 range.
Goldman, Sachs & Co., BofA Merrill Lynch, and Piper Jaffray & Co. acted as book-running managers, and William Blair & Company and Stifel Nicolaus Weisel acted as co-managers for this offering. Latham & Watkins LLP served as legal counsel to Tilly’s in connection with the offering.
Tilly's is a fast-growing destination specialty retailer of West Coast inspired apparel, footwear and accessories.
In fiscal 2011, Tilly's increased net sales to $400.6 million from $332.6 million in fiscal 2010, or 20%, and increased operating income to $34.9 million from $24.9 million in fiscal 2010, or 40%. Tilly's comparable store sales increased 10.7% in fiscal year 2011 after a 6.7% increase in fiscal year 2010.
Goldman, Sachs & Co., BofA Merrill Lynch, and Piper Jaffray & Co. acted as book-running managers, and William Blair & Company and Stifel Nicolaus Weisel acted as co-managers for this offering. Latham & Watkins LLP served as legal counsel to Tilly’s in connection with the offering.
Tilly's is a fast-growing destination specialty retailer of West Coast inspired apparel, footwear and accessories.
In fiscal 2011, Tilly's increased net sales to $400.6 million from $332.6 million in fiscal 2010, or 20%, and increased operating income to $34.9 million from $24.9 million in fiscal 2010, or 40%. Tilly's comparable store sales increased 10.7% in fiscal year 2011 after a 6.7% increase in fiscal year 2010.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- William Blair on Sage Therapeutics (SAGE): 'we have difficulty envisioning what additional data could be generated to support a resubmission'
- William Blair Starts On Holding AG (ONON) at Outperform, 'e see a path to three-year revenue growth above 25%'
Create E-mail Alert Related Categories
Hot IPOs, IPOs, Momentum MoversRelated Entities
Piper Jaffray, Stifel, William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!